Relyvrio and Alcohol/Food Interactions
There are 3 alcohol/food/lifestyle interactions with Relyvrio (sodium phenylbutyrate / taurursodiol).
Caffeine Taurursodiol
Moderate Drug Interaction
Taurursodiol may alter the blood levels and effects of caffeine. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Nicotine Taurursodiol
Moderate Drug Interaction
Taurursodiol may alter the blood levels and effects of nicotine. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Sodium Phenylbutyrate Food
Moderate Food Interaction
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: Coadministration with a high-fat meal may reduce the rate and extent of absorption of sodium phenylbutyrate. When a single 3 g-1 g dose of sodium phenylbutyrate-taurursodiol (sodium phenylbutyrate-ursodoxicoltaurine) was administered to healthy volunteers in the presence of a high-fat, high-calorie meal (approximately 800 to 1000 calories; 500 to 600 calories from fat, 250 calories from carbohydrate, 150 calories from protein), sodium phenylbutyrate peak plasma concentration (Cmax) decreased by 75% and systemic exposure (AUC) decreased by 55%. The Cmax for taurursodiol was not significantly affected, but AUC was increased by 46%. The clinical significance of these changes has not been established. In premarketing studies, patients were advised to take the drug before a meal.
MANAGEMENT: The prescribing information recommends administration of sodium phenylbutyrate-taurursodiol before a meal or snack, particularly in patients of low body weight (less than 70 kg).
Switch to professional interaction data
Relyvrio drug interactions
There are 588 drug interactions with Relyvrio (sodium phenylbutyrate / taurursodiol).
Relyvrio disease interactions
There are 4 disease interactions with Relyvrio (sodium phenylbutyrate / taurursodiol) which include:
More about Relyvrio (sodium phenylbutyrate / taurursodiol)
- Relyvrio consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Radicava
Radicava (edaravone) is used to treat amyotrophic lateral sclerosis (ALS). Includes Radicava side ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Qalsody
Qalsody (tofersen) is a prescription medicine used to treat amyotrophic lateral sclerosis (ALS) in ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.